| Literature DB >> 31637482 |
Pierre-Yves Salaün1, Ronan Abgral2, Olivier Malard3, Solène Querellou-Lefranc2, Gilles Quere4, Myriam Wartski5, Romain Coriat6, Elif Hindie7, David Taieb8, Antoine Tabarin9, Antoine Girard10, Jean-François Grellier11, Isabelle Brenot-Rossi12, David Groheux13, Caroline Rousseau14, Désirée Deandreis15, Jean-Louis Alberini16, Caroline Bodet-Milin17, Emmanuel Itti18, Olivier Casasnovas19, Françoise Kraeber-Bodere14,17, Philippe Moreau20, Arnaud Philip21, Corinne Balleyguier22, Alain Luciani23, Florent Cachin24.
Abstract
Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.Entities:
Keywords: Computed tomography; Methodological approval; Positron emission tomography
Mesh:
Year: 2019 PMID: 31637482 DOI: 10.1007/s00259-019-04553-8
Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN: 1619-7070 Impact factor: 9.236